



For more information, please contact:  
Adriana Jenkins  
Yates Public Relations  
617-744-1713

## **New Research Demonstrates Potential of Novel Nanoscale MR-based Technology for Rapid, Portable Diagnostic Testing**

### *New Sensitivity Data Presented at AAAC Oak Ridge Conference*

*Baltimore, MD and Cambridge, MA -- April 16, 2009* – T2 Biosystems, Inc., a company developing the first portable medical diagnostic products that combine nanotechnology and miniaturized magnetic resonance (MR) technology, today announced significant research findings that support the further development of its core technology, which ultimately will offer rapid, portable diagnostic testing at the point of need. The findings, which demonstrate sensitive detection of targets in unprocessed samples such as whole blood and urine, were presented today in a poster presentation “*Universal nanoparticle-based platform for rapid clinical diagnostics*” at the American Association for Clinical Chemistry’s 41<sup>st</sup> Annual Oak Ridge Conference in Baltimore, MD.

T2 Biosystems is developing the next generation of medical diagnostic products through its proprietary technology, which combines nanotechnology and the miniaturization of proven MR technology. Building on dozens of prior published studies, this new research demonstrates the potential of these new magnetic resonance-based diagnostics to offer improved speed, accuracy and efficiency as well as portability to a broader range of settings including doctor’s offices, homes and hospitals.

The findings presented at the Oak Ridge Conference demonstrate and validate the range of nanoparticle assays T2 has successfully developed to detect miniscule amounts (nanomolar to picomolar) of target substances within unprocessed samples of whole blood, plasma and urine. In the study, researchers evaluated T2’s technology to accurately and efficiently analyze samples in a single-step process, as opposed to versus conventional clinical diagnostics technology which requires multiple processes and complex instrumentation.

“This data is a continued validation of the breakthrough potential of this technology,” said John McDonough, CEO of T2 Biosystems. “T2 is on track to produce a prototype instrument this year to fully explore the technology’s potential of enabling immediate, accurate diagnostic testing for nearly any health condition, in nearly any setting.”

T2 Biosystems’ technology has been validated in multiple published journal articles and has shown to accurately analyze viruses, bacteria, proteins, hormones, DNA, small molecules and other diagnostic targets. The Company is developing a pipeline of diagnostic products based on

its technology, including devices for hospitals, diagnostic laboratories and medical offices, as well as individual patients.

### **About T2 Biosystems**

T2 Biosystems is a private biotechnology company developing next-generation medical diagnostic products using its proprietary technology, combining nanotechnology and miniaturized magnetic resonance (MRI) technology to provide rapid, accurate and portable diagnostics. T2 Biosystems was founded in 2006 by renowned researchers from the Massachusetts Institute of Technology, Harvard University, Harvard Medical School and Massachusetts General Hospital, and has assembled a world-class team, board of directors and scientific advisory board that collectively have a proven track record of translating technologic innovations into breakthrough products, building significant corporate value. T2 Biosystems is located in Cambridge, Massachusetts. For more information, please visit the company's website at [www.t2biosystems.com](http://www.t2biosystems.com).

###